MA41377A - Gel intestinal de lévodopa et de carbidona et procédés d'utilisation - Google Patents
Gel intestinal de lévodopa et de carbidona et procédés d'utilisationInfo
- Publication number
- MA41377A MA41377A MA041377A MA41377A MA41377A MA 41377 A MA41377 A MA 41377A MA 041377 A MA041377 A MA 041377A MA 41377 A MA41377 A MA 41377A MA 41377 A MA41377 A MA 41377A
- Authority
- MA
- Morocco
- Prior art keywords
- carbidona
- levodopa
- procedures
- intestinal gel
- intestinal
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105565P | 2015-01-20 | 2015-01-20 | |
| US201562272922P | 2015-12-30 | 2015-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41377A true MA41377A (fr) | 2017-11-28 |
Family
ID=55410198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041377A MA41377A (fr) | 2015-01-20 | 2016-01-19 | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10117843B2 (fr) |
| EP (2) | EP4470611A3 (fr) |
| JP (4) | JP2018503686A (fr) |
| KR (1) | KR20170103967A (fr) |
| CN (2) | CN107427463A (fr) |
| AU (1) | AU2016209420B2 (fr) |
| BR (1) | BR112017015613B1 (fr) |
| CA (1) | CA2974203A1 (fr) |
| IL (1) | IL253487A0 (fr) |
| MA (1) | MA41377A (fr) |
| MX (1) | MX384262B (fr) |
| PH (1) | PH12017501304A1 (fr) |
| RU (1) | RU2017129375A (fr) |
| SG (1) | SG11201705964YA (fr) |
| TW (1) | TW201639556A (fr) |
| WO (1) | WO2016118556A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2021103000A (ru) | 2014-10-21 | 2021-03-01 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| WO2016179540A1 (fr) | 2015-05-06 | 2016-11-10 | Synagile Corporation | Suspensions pharmaceutiques contenant des particules de médicament, dispositifs pour leur administration, et leurs procédés d'utilisation |
| BR112019001082A2 (pt) * | 2016-07-20 | 2019-04-30 | Abbvie Inc. | gel intestinal de levodopa e carbidopa e métodos de uso |
| EP3880210A1 (fr) | 2018-11-15 | 2021-09-22 | Abbvie Inc. | Formulations pharmaceutiques pour une administration sous-cutanée |
| CN119510592A (zh) * | 2023-08-22 | 2025-02-25 | 上海汉都医药科技有限公司 | 一种含有卡比多巴的药物中肼含量的检测方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3132171A (en) | 1962-06-18 | 1964-05-05 | Strong Cobb Arner Inc | 3, 4-diphosphatophenyl-alanine and process for making same |
| US4618484A (en) | 1983-03-30 | 1986-10-21 | Yale University | Composition and method for treatment of melanomas |
| ES2070994T3 (es) | 1989-04-20 | 1995-06-16 | Zambon Spa | Profarmaco de dopamina. |
| IT1255471B (it) | 1992-07-30 | 1995-11-02 | Zambon Spa | Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono |
| SE9203594D0 (sv) * | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| WO2004069146A2 (fr) | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Derives d'amide l-dopa et utilisations de ceux-ci |
| KR20090057349A (ko) * | 2006-05-31 | 2009-06-05 | 솔베이 파머슈티컬스 게엠베하 | 레보도파／칼비도파의 ２４시간의 장기간 장내투여 |
| SG10201505101VA (en) | 2009-05-19 | 2015-07-30 | Neuroderm Ltd | Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| JP2013520521A (ja) | 2009-11-09 | 2013-06-06 | ゼノポート，インコーポレーテッド | レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法 |
| SI2640358T1 (en) | 2010-11-15 | 2018-05-31 | Neuroderm Ltd. | Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof |
| SG191090A1 (en) * | 2010-12-10 | 2013-07-31 | Synagile Corp | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| US8765189B2 (en) | 2011-05-13 | 2014-07-01 | Howmedica Osteonic Corp. | Organophosphorous and multivalent metal compound compositions and methods |
| US10195350B2 (en) * | 2011-08-31 | 2019-02-05 | Abbvie Inc. | Sealing arrangement for syringe |
| CN105209029A (zh) | 2013-03-13 | 2015-12-30 | 纽罗德姆有限公司 | 帕金森病的治疗方法 |
| ES2957768T3 (es) * | 2013-11-05 | 2024-01-25 | Synagile Corp | Suministro continuo de fármacos a través de la boca |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
-
2016
- 2016-01-19 MA MA041377A patent/MA41377A/fr unknown
- 2016-01-20 US US15/001,392 patent/US10117843B2/en active Active
- 2016-01-20 CA CA2974203A patent/CA2974203A1/fr not_active Abandoned
- 2016-01-20 CN CN201680016049.3A patent/CN107427463A/zh active Pending
- 2016-01-20 KR KR1020177022953A patent/KR20170103967A/ko not_active Withdrawn
- 2016-01-20 MX MX2017009325A patent/MX384262B/es unknown
- 2016-01-20 WO PCT/US2016/014005 patent/WO2016118556A1/fr not_active Ceased
- 2016-01-20 SG SG11201705964YA patent/SG11201705964YA/en unknown
- 2016-01-20 CN CN202310053820.6A patent/CN116036064A/zh active Pending
- 2016-01-20 AU AU2016209420A patent/AU2016209420B2/en active Active
- 2016-01-20 EP EP24194552.6A patent/EP4470611A3/fr not_active Withdrawn
- 2016-01-20 TW TW105101753A patent/TW201639556A/zh unknown
- 2016-01-20 JP JP2017556790A patent/JP2018503686A/ja active Pending
- 2016-01-20 EP EP16706041.7A patent/EP3247330A1/fr not_active Withdrawn
- 2016-01-20 BR BR112017015613-0A patent/BR112017015613B1/pt not_active IP Right Cessation
- 2016-01-20 RU RU2017129375A patent/RU2017129375A/ru not_active Application Discontinuation
-
2017
- 2017-07-14 IL IL253487A patent/IL253487A0/en unknown
- 2017-07-18 PH PH12017501304A patent/PH12017501304A1/en unknown
-
2018
- 2018-10-16 US US16/161,940 patent/US20190142777A1/en not_active Abandoned
-
2020
- 2020-03-18 US US16/822,892 patent/US20210046029A1/en not_active Abandoned
- 2020-12-24 JP JP2020214665A patent/JP7232235B2/ja active Active
-
2023
- 2023-02-16 JP JP2023022208A patent/JP2023058678A/ja not_active Ceased
-
2024
- 2024-07-04 JP JP2024107963A patent/JP2024129122A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116036064A (zh) | 2023-05-02 |
| RU2017129375A (ru) | 2019-02-21 |
| PH12017501304A1 (en) | 2018-02-05 |
| EP3247330A1 (fr) | 2017-11-29 |
| CA2974203A1 (fr) | 2016-07-28 |
| WO2016118556A1 (fr) | 2016-07-28 |
| JP2018503686A (ja) | 2018-02-08 |
| US10117843B2 (en) | 2018-11-06 |
| IL253487A0 (en) | 2017-09-28 |
| SG11201705964YA (en) | 2017-08-30 |
| US20160206584A1 (en) | 2016-07-21 |
| US20210046029A1 (en) | 2021-02-18 |
| EP4470611A2 (fr) | 2024-12-04 |
| JP2024129122A (ja) | 2024-09-26 |
| CN107427463A (zh) | 2017-12-01 |
| JP2023058678A (ja) | 2023-04-25 |
| JP7232235B2 (ja) | 2023-03-02 |
| US20190142777A1 (en) | 2019-05-16 |
| AU2016209420B2 (en) | 2021-05-20 |
| JP2021073186A (ja) | 2021-05-13 |
| MX384262B (es) | 2025-03-14 |
| EP4470611A3 (fr) | 2025-02-19 |
| BR112017015613A2 (en) | 2018-03-13 |
| KR20170103967A (ko) | 2017-09-13 |
| MX2017009325A (es) | 2018-02-09 |
| RU2017129375A3 (fr) | 2019-08-05 |
| BR112017015613B1 (pt) | 2023-11-28 |
| TW201639556A (zh) | 2016-11-16 |
| AU2016209420A1 (en) | 2017-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3390624A4 (fr) | Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation | |
| EP3678681A4 (fr) | Variants de l'interleukine-18 et leurs procédés d'utilisation | |
| EP3303634A4 (fr) | Variants de cas9 et procédés d'utilisation associés | |
| EP3704239A4 (fr) | Compositions de casz et procédés d'utilisation | |
| MA44507A (fr) | Récepteurs chimères de flt3 et leurs procédés d'utilisation | |
| HRP20251600T1 (hr) | Sustav i postupci | |
| EP3377612A4 (fr) | Expression fonctionnelle de monooxygénases et procédés d'utilisation | |
| EP3394065A4 (fr) | Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés | |
| EP3303435A4 (fr) | Hydrofluoroléfines et procédés d'utilisation associés | |
| EP3352774A4 (fr) | Compositions de flavonoïdes et procédés d'utilisation | |
| EP3436048A4 (fr) | Néoantigènes et leurs procédés d'utilisation | |
| EP3517577A4 (fr) | Gel de silicone réactif durcissable et son utilisation | |
| EP3307762A4 (fr) | Variants de cas9 rapporteurs et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3341027A4 (fr) | Complexes de transfection et leurs procédés d'utilisation | |
| MA40069A (fr) | Molécules de liaison trispécifiques et leurs procédés d'utilisation | |
| EP3319610A4 (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3271352A4 (fr) | Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci | |
| EP3710430A4 (fr) | Inhibiteurs d'acss2 et leurs procédés d'utilisation | |
| MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3635000A4 (fr) | Manabodies et procédés d'utilisation | |
| EP3621660A4 (fr) | Compositions et procédés d'utilisation de capsides arc | |
| EP3314218A4 (fr) | Distributeurs de dose mesurée et leurs procédés d'utilisation | |
| EP3349851A4 (fr) | Polypeptides photosensibles et leurs procédés d'utilisation | |
| EP3386927A4 (fr) | Compositions polymères et procédés d'utilisation |